|
Published studies of adjuvant chemotherapy in early stage ovarian cancer |
|||||
| Study |
Type of study |
Treatment |
Pts |
5y RFS |
5y OS |
|
|
|||||
| Young, 19906 |
Prospective, randomized |
Melphalan 32P |
68 73 |
80% 80% |
81% 78% |
| Vergote, 19921 |
Prospective, randomized |
Cisplatin 32P |
171 169 |
81% 83% |
75% 81% |
| Bolis, 19955 |
Prospective, randomized |
Cisplatin 32P |
82 79 |
85% 65% |
81% 79% |
| Young, 199920 |
Prospective, randomized |
Cyclo/Cisplatin 32P |
107 98 |
77% 66% |
84% 76% |
| Trope, 20007 |
Prospective, randomized |
Carboplatin No treatment |
81 81 |
70% 71% |
86% 85% |
| Trimbos, 20038 |
Prospective, randomized |
Platinum-based No treatment |
224 224 |
76%* 68% |
85% 78% |
| ICON1, 20039 |
Prospective, randomized |
Platinum-based No treatment |
241 236 |
73%@ 62% |
79%# 70% |
| Present study |
Retrospective, nonrandomized |
Paclitaxel/Carboplatin |
69 |
79% |
87% |
|
RFS: relapse-free survival; OS: overall survival; *: p = 0.02; @: p = 0.01; #: p = 0.03 | |||||
Bamias et al. BMC Cancer 2006 6:228 doi:10.1186/1471-2407-6-228 |
|||||